We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One proposed cocktail, baloxavir marboxil, natamycin and RU85053, targets three viral proteins respectively, 3CL Main protease, papain-like protease and RdRp.
The research group is working on developing new drug candidates against SARS-CoV-2 by exploring DrugBank database compounds as an inhibitor of SARS-CoV-2 main protease, a key enzyme required for SARS-CoV-2 assembly and multiplication.